Medical University of Vienna, Department of Internal Medicine III Trials

Medical University of Vienna, Department of Internal Medicine III	Welcome, Profile Billing Logout

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Wolf, Peter

PLE_microbio, NCT04985526: Skin Microbiome and Polymorphic Light Eruption

Recruiting

N/A

Europe

Octeniderm (octenidine dihydrochloride, 1-propanol, 2- propanol)

Medical University of Graz

Polymorphic Light Eruption

06/22

06/23

BioUV2017, NCT03340155: Mechanisms of Action of Photo(Chemo)Therapy in Skin Diseases

Recruiting

N/A

240

Europe

Photo(chemo)therapy

Medical University of Graz

Psoriasis, Cutaneous T Cell Lymphoma, Lymphoproliferative Disorders, Eczema, Lichen Planus, Prurigo, Pruritus, Polymorphic Light Eruption, Graft Vs Host Disease, Mastocytosis, Vitiligo

10/22

NCT04954573: Study on the Treatment With Water-filtered Infrared-A (wIRA) Radiation in Patients With Morphea and Sclerotic Graft-versus-host Disease

Recruiting

N/A

Europe

infrared-A (wIRA)

Medical University of Graz

Morphea (Circumscribed Scleroderma), Sclerotic Graft-versus-host Disease (GVHD)

01/25

04/25

Luger, Anton

NCT02817360: NT-proBNP Selected Prevention of Cardiac Events in Diabetic Patients

Recruiting

2400

Europe, RoW

RAS-antagonist and beta-blocker up-to maximal dosages, Enalapril 40mg/d, Ramipril 10mg/d, Lisinopril 40mg/d, Cilazapril 5mg/d, Perindopril 8mg/d, Captopril 150mg/d, Spirapril 24mg/d, Quinapril 40mg/d, Trandolapril 4mg/d, Zofenopril 60mg/d, Fosinopril 40mg/d, Candesartan 32mg/d, Valsartan 320mg/d, Irbesartan 300mg/d, Losartan 150mg/d, Eprosartan 800mg/d, Bisoprolol 10mg/d, Metoprololsuccinat 200mg/d, Carvedilol 50mg/d (100mg/d if weight is > 85kg), Nebivolol 10mg/d, RAS-antagonist and beta-blocker none or at stable dose

Martin Huelsmann

Heart Diseases, Diabetes Mellitus, Type 2

12/25

12/26

Trauner, Michael

COMBAT_T2_NASH, NCT04639414: Combined Active Treatment in Type 2 Diabetes With NASH

Recruiting

192

Europe

Empagliflozin 10mg oral tablet / Semaglutide 1mg pen injector, Jardiance(R), Ozempic(R), Empagliflozin 10mg oral tablet and placebo pen injector matching semaglutide, Jardiance(R), Placebo matching empagliflozin and placebo pen injector matching semaglutide, Control / Placebo

The Deutsche Diabetes Forschungsgesellschaft e.V., Boehringer Ingelheim, German Center for Diabetes Research, Federal Ministry of Health, Germany, Ministry of Innovation, Science and Research in North Rhine-Westphalia, Novo Nordisk A/S

Type 2 Diabetes, Non-alcoholic Steatohepatitis (NASH), Non-alcoholic Fatty Liver Disease (NAFLD)

01/25

12/25

NCT03872921: norUrsodeoxycholic Acid vs Placebo in PSC

Recruiting

300

Europe

norUrsodeoxycholic Acid, NUC

Dr. Falk Pharma GmbH

Primary Sclerosing Cholangitis

04/21

12/23

NCT04594694 / 2018-002575-17: Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Participants With PBC

Active, not recruiting

Europe, RoW

Obeticholic acid, Bezafibrate 200 MG, OCA Placebo, Bezafibrate 200 mg Placebo, Bezafibrate 400 MG, Bezafibrate 400 mg Placebo, OCA, Bezafibrate

Intercept Pharmaceuticals

Primary Biliary Cholangitis

10/25

12/25

NCT05083390 / 2018-003443-31: Norursodeoxycholic Acid vs. Placebo in NASH

Recruiting

363

Europe

norUrsodeoxycholic acid, norucholic acid, norUDCA, NCA

Dr. Falk Pharma GmbH, Dr. Falk Pharma GmbH,

Nonalcoholic Steatohepatitis

01/25

04/25

ADLH, NCT03897218: Dietary Modulation of Intestinal Microbiota as Trigger of Liver Health: Role of Bile Acids - "A Diet for Liver Health"

Completed

N/A

Europe

oatmeal flakes with prebiotic food supplements, millet flakes

RWTH Aachen University

NASH - Nonalcoholic Steatohepatitis

04/22

Ludvik, Bernhard

COMBAT_T2_NASH, NCT04639414: Combined Active Treatment in Type 2 Diabetes With NASH

Recruiting

192

Europe

Type 2 Diabetes, Non-alcoholic Steatohepatitis (NASH), Non-alcoholic Fatty Liver Disease (NAFLD)

01/25

12/25

NCT02817360: NT-proBNP Selected Prevention of Cardiac Events in Diabetic Patients

Recruiting

2400

Europe, RoW

Martin Huelsmann

Heart Diseases, Diabetes Mellitus, Type 2

12/25

12/26

NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

Recruiting

12500

Europe, Canada, Japan, US, RoW

Lepodisiran Sodium, LY3819469, Placebo

Eli Lilly and Company

Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)

03/29

NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Renal Function in Adults Living With Obesity (TRIUMPH-OUTCOMES)

Recruiting

10000

Europe, Canada, US, RoW

Retatrutide, LY3437943, Placebo

Eli Lilly and Company

Overweight and Obesity

02/29

ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Recruiting

2620

Europe, US, RoW

Orforglipron, LY3502970, Insulin Glargine

Eli Lilly and Company

Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease

04/25

12/25

SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

Active, not recruiting

15374

Europe, Canada, Japan, US, RoW

Tirzepatide, LY3298176, Placebo

Eli Lilly and Company

Obesity, Overweight

10/27

Ver-A-T1D, NCT04545151 / 2020-000435-45: Verapamil SR in Adults With Type 1 Diabetes

Recruiting

138

Europe

Verapamil SR 120 mg, VeraHEXAL KHK 120 mg, Isoptin retard 120 mg, Placebo, Matching Placebo for Verapamil SR 120 mg

Medical University of Graz, Juvenile Diabetes Research Foundation

Diabetes Mellitus, Type 1

04/25

04/26

TREASURE-CKD, NCT05536804 / 2021-005273-47: A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

Recruiting

140

Europe, Canada, US, RoW

Tirzepatide, Placebo

Eli Lilly and Company, Eli Lilly and Company

Overweight, Obesity, Chronic Kidney Disease, Type 2 Diabetes, T2D

01/26

02/26

Krebs, Michael

NCT02817360: NT-proBNP Selected Prevention of Cardiac Events in Diabetic Patients

Recruiting

2400

Europe, RoW

Martin Huelsmann

Heart Diseases, Diabetes Mellitus, Type 2

12/25

12/26

Scherer, Thomas

POMPE, NCT05943678: Novel Metabolic Muscular Biomarkers in Pompe Disease - a Non-invasive Magnetic Resonance Exploratory Pilot Study.

Recruiting

N/A

Europe

Siemens Magnetom 7T Plus

Medical University of Vienna

Pompe Disease, McArdle Disease

08/28

10/28

ECLip Registry, NCT03553420: Registry for Patients With Lipodystrophy

Recruiting

N/A

5000

Europe, RoW

University of Ulm, Sorbonne University, University Hospital, Lille, University of Cambridge, Endocrinology Research Centre, Moscow, University of Leipzig, University of Amsterdam, Dokuz Eylul University, IRCCS Azienda Ospedaliero-Universitaria di Bologna, University of Rome Tor Vergata, University of Pisa, University of Santiago de Compostela, Università degli Studi del Piemonte Orientale "Amedeo Avogadro", University Hospital Muenster, Szeged University, Centro Hospitalar do Porto, University Medical Centre Ljubljana, Medical University of Vienna, Ostschweizer Kinderspital

Lipodystrophy Acquired, Lipodystrophy Congenital

01/68

Krssak, Martin

No trials found

Winhofer, Yvonne

No trials found



	Diseases Companies Products Productz Mechanisms of Action Sites